Indaptus Therapeutics, Inc. (INDP): Cash & Equivalents
$8.51M
As of 2025-12-31
$7.55M
As of 2026-06-30
-4.0%
3-year compound annual growth
+39.0%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.51M | +47.0% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $5.79M | -56.7% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $13.36M | +38.8% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $9.63M | -75.4% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $39.13M | n/m | 2023-03-17, Balance as of period end |
| 2020-12-31 | $1.64M | n/a | 2022-03-21, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | $8.51M | +47.0% |
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | $6.12M | -54.0% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $7.56M | -85.2% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $5.53M | +14.6% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $4.89M | -65.0% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $796.8K | -45.9% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $0 | n/a |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $7.03M | -28.8% |
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | $1.56M | -67.5% |
Compare INDP, PMN, KALA, CANF side by side · Screen every company in Pharmaceutical Preparations ↗